Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence

Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini Department of Medicine, University of Padova, Padova 35128, ItalyCorrespondence: Gian Paolo FadiniDepartment of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, ItalyTel +39 49 8214318Fax +29 49 8212184Email gianpaolo.fadini@u...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bonora BM, Avogaro A, Fadini GP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	type 2 diabetes sodium-glucose cotransporter-2 inhibitors cardiovascular effects renal effects review Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/57add5ecf2e84f1399d0d1489b66b187
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57add5ecf2e84f1399d0d1489b66b187
record_format	dspace
spelling	oai:doaj.org-article:57add5ecf2e84f1399d0d1489b66b1872021-12-02T06:33:57ZExtraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence1178-7007https://doaj.org/article/57add5ecf2e84f1399d0d1489b66b1872020-01-01T00:00:00Zhttps://www.dovepress.com/extraglycemic-effects-of-sglt2-inhibitors-a-review-of-the-evidence-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini Department of Medicine, University of Padova, Padova 35128, ItalyCorrespondence: Gian Paolo FadiniDepartment of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, ItalyTel +39 49 8214318Fax +29 49 8212184Email gianpaolo.fadini@unipd.itAbstract: Patients with type 2 diabetes (T2D) are often overweight/obese and affected by arterial hypertension, dyslipidaemia, and have high serum levels of uric acid. Moreover, T2D patient have a higher risk of developing cardiovascular or renal complications, which are leading causes of morbidity and mortality in this population. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a new class of glucose-lowering medications that block the reabsorption of glucose in the kidney, thereby increasing urinary glucose excretion, and lowering blood glucose levels. The beneficial effects of SGLT2 inhibition extend beyond glycaemic control, and include improvement in blood pressure, body weight, uric acid concentrations, liver steatosis, oxidative stress, and inflammation. In dedicated cardiovascular outcome trials, SGLT2i treatment was associated with a significant reduction in the rate of cardiovascular events and renal endpoints. In this review, we summarize the evidence for extra-glycemic effects of SGLT2i and the potential mechanisms driving cardiorenal protection exerted by this class of medications.Keywords: type 2 diabetes, sodium-glucose cotransporter-2 inhibitors, cardiovascular effects, renal effects, reviewBonora BMAvogaro AFadini GPDove Medical Pressarticletype 2 diabetessodium-glucose cotransporter-2 inhibitorscardiovascular effectsrenal effectsreviewSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 161-174 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes sodium-glucose cotransporter-2 inhibitors cardiovascular effects renal effects review Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes sodium-glucose cotransporter-2 inhibitors cardiovascular effects renal effects review Specialties of internal medicine RC581-951 Bonora BM Avogaro A Fadini GP Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
description	Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini Department of Medicine, University of Padova, Padova 35128, ItalyCorrespondence: Gian Paolo FadiniDepartment of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, ItalyTel +39 49 8214318Fax +29 49 8212184Email gianpaolo.fadini@unipd.itAbstract: Patients with type 2 diabetes (T2D) are often overweight/obese and affected by arterial hypertension, dyslipidaemia, and have high serum levels of uric acid. Moreover, T2D patient have a higher risk of developing cardiovascular or renal complications, which are leading causes of morbidity and mortality in this population. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a new class of glucose-lowering medications that block the reabsorption of glucose in the kidney, thereby increasing urinary glucose excretion, and lowering blood glucose levels. The beneficial effects of SGLT2 inhibition extend beyond glycaemic control, and include improvement in blood pressure, body weight, uric acid concentrations, liver steatosis, oxidative stress, and inflammation. In dedicated cardiovascular outcome trials, SGLT2i treatment was associated with a significant reduction in the rate of cardiovascular events and renal endpoints. In this review, we summarize the evidence for extra-glycemic effects of SGLT2i and the potential mechanisms driving cardiorenal protection exerted by this class of medications.Keywords: type 2 diabetes, sodium-glucose cotransporter-2 inhibitors, cardiovascular effects, renal effects, review
format	article
author	Bonora BM Avogaro A Fadini GP
author_facet	Bonora BM Avogaro A Fadini GP
author_sort	Bonora BM
title	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
title_short	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
title_full	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
title_fullStr	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
title_full_unstemmed	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
title_sort	extraglycemic effects of sglt2 inhibitors: a review of the evidence
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/57add5ecf2e84f1399d0d1489b66b187
work_keys_str_mv	AT bonorabm extraglycemiceffectsofsglt2inhibitorsareviewoftheevidence AT avogaroa extraglycemiceffectsofsglt2inhibitorsareviewoftheevidence AT fadinigp extraglycemiceffectsofsglt2inhibitorsareviewoftheevidence
_version_	1718399813848924160

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence

Ejemplares similares